Many vascular diseases in diabetes are known to be associated with the activation of the diacylglycerol (OAG)protein kinase C (PKC) pathway. The major source of OAG that is elevated in diabetes is de novo synthesis from glycolytic intermediates. Among the various PKC isoforms, the &#946;-isoform has been shown to be persistently activated in diabetic animals. Multiple lines of evidence have shown that many vascular alterations in diabetes such as a decrease in the activity of Na+-K+-adenosine triphosphatase (Na+-K+-ATPase), and increases in extracellular matrix, cytokines, permeability, contractility, and cell proliferation -are caused by activation of PKC.lnhibition of PKC by two different kinds of PKC inhibitors, LY333531 , a selective PKC-&#946;-isoform inhibitor, and d-&#945;-tocopherol, were able to prevent or reverse the various vascular dysfunctions in diabetic rats. These results have also provided in vivo evidence that OAG-PKC activation could be responsible for the hyperglycemiainduced vascular dysfunctions in diabetes. Clinical studies are now being performed to clarify the pathogenic roles of the OAG-PKC pathway in developing vascular complications in diabetic patients.
D
iabetic vascular complications occur in many tis sues, including microvasculature and macrovas culature, nerve, heart, and others (1) . These complications are the most common causes of mortality, of end-stage renal disease, and of blindness in diabetic patients worldwide.
The results of the Diabetes Control and Complications Trial (2) have shown that hyperglycemia plays a major role in the development and progression of diabetic vascular and neurological complications. However, it is clinically very difficult to achieve near-normal glu cose control in individual patients with diabetes.
Several theories have been proposed to explain the relationship between diabetes or hyperglycemia and diabetic vascular complications (3) . A single hypothesis has not solved this abstract riddle.
Correspondence to: G.L. King, Section on Vascular Cell Biology, Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215 U.S.A. Diabetic vascular complications have common characteristics. First, there is chronicity in their development. Second, diabetic vascular diseases are the result of the specific metabolic alterations found in diabetes, such as hyperglycemia. Third, genetics also plays an important role, as many diabetic patients do not suffer from retinopathy or nephropathy (1) .
In this review, we will focus only on the activation of one specific metabolic pathway called the diacylglycerol (DAG) and protein kinase C (PKC) pathway, and on its pathogenic role in diabetic vascular complications.
DAG-PKC P ATHWAY AND MECHANISM OF ITS ACTIVATION IN DIABETES MELLITUS
Protein kinase C comprises a family of at least 12 isoforms of serine threonine kinases (4), which are classified into subfamilies on the basis of their enzymatic and structural properties. The s ubfamilies are conventional PKCs (cPKCs: &#945;, &#946;1, &#946;2, &#978;), new or novel PKCs (nPKCs: &#948;, &#949;,11, &#920;, &#956;), and atypical PKCs (aPKCs: &#958;, &#955;). cPKCs are activated by phosphatidylserine (PS) in a Ca2+-dependent manner, and they contain two cyteine-rich, zinc finger-Iike motifs (C1 region, a binding site ofDAG or phorbol ester), and Ca2+/phospholipids (C2 region). The PKC &#946; gene is alternatively spliced to produce two gene products, &#946;1 and &#946;2, which differ only in their extreme C-terminal end. nPKCs are Ca2+-insensitive because of the absence of the C2 region, but they are still activated by DAG or phorbol esters in the presence ofPS. aPKCs are, as the nPKCs are, Ca2+-insensitive. They do not respond to phorbol ester/DAG, but they can be activated by PS.
Many in vivo (5-7) and in vitro (5, 6, 8) studies have suggested that increased DAG levels in vascular tis sues, a physiological activator ofPKC, is related with PKC activation in diabetes mellitus (Table 1) . Xia et al (9) showed that DAG contents were chronically increased in the aorta of diabetic dogs even after five years of disease. These results strongly suggested that the activation of the DAG-PKC pathway can be persistently maintained without downregulation, which is consistent with the fact that diabetic microvascu lar complications are known to develop several years after the onset of diabetes.
The source of DAG that activates PKC can be derived from the hydrolysis of phosphatidylinositides (PIs) or from the metabolism ofphosphatidylcholine (PC) by phospholipase C (PLC) or phospholipase D (PLD ). Alternatively, DAG can be synthesized de novo from glycolytic intermediates. In metabolic labeling studies, we have reported that the incorporation of glucose into the glycerol backbone of DAG was in creased by hyperglycemia, suggesting that increased DAG contents were partly derived from de novo pathway (9, 10) .
Although PKC isoforms other than PKC &#946; (such as &#945;, &#948;, &#949;) are reported to be increased in diabetic retina (5) and glomeruli (11) , the PKC &#946;-isoform is persistently activated in aorta and heart of diabetic rats (6) , and in cultured aortic smooth muscle cells exposed to high glucose (12) .
In diabetic state, many vascular alterations at the cellular, histological, and functional level have been reported. It is not surprising that all these changes are associated with DAG-PKC activation, because multiple lines of evidence support the relationship ( Figure 1 ). The available data regarding this association will be reviewed below.
Na+-K+-Adenosine Triphosphatase: Na+-K+-adenosine triphosphatase (Na+-K+-ATPase), a component of sodium pump, has been known to be decreased in vascular and neuronal tissues of diabetic patients and animals. However, the mechanism by which hyperglycemia or diabetes inhibits Na+-K+-ATPase has not been clarified. Recently, we reported that the inhibition of Na+-K+-ATPase by hyperglycemia was due to the activation of PKC with subsequent increase in cytosolic phospholipase A2 (cPLA2) activity (13) . The activation of cPLA2 will increase the production of arachidonic acid and prostaglandin E2 (PGE2) levels, which have been reported to inhibit Na+-K+-ATPase. We have also found that specific inhibitors of PKC and cPLA2 will prevent the inhibition of Na+-K+ATPase induced by hyperglycemia.
BASEMENT MEMBRANE THICKENING AND EXTRACELLULAR MATRIX CHANGE
The most prominent histologic change in diabetic vasculature is the thickening of capillary basement membrane. In mesangium of diabetic patients, changes in the basement membrane, including in creases in type IV and type VI collagen, and in fibro nectin, and decreases in proteoglycans, have been observed (14) . Similar changes were reproduced in cultured mesangial and endothelial cells exposed to hyperglycemia (8) . The use ofPKC inhibitors has been shown to prevent this effect of hyperglycemia. The activation ofPKC has been reported to regulate gene expression of type IV collagen, fibronectin, and transforming growth factor-&#946; (TGF&#946;) by acting through the PKC-responsive element in the promoter regions, such as the activator protein-1 (AP-1) region (15) .
ALTERED V ASCULAR CONTRACTILITY AND BLOOD FLOW
Abnormal hemodynamic changes such as blood flow and contractility are frequently observed in many tissues of diabetic animals and patients. In the kidney, it has been well established that hemo dynamic alterations such as increased renal glomerular filtration rate (GFR) and modest increase of renal blood flow precede diabetic nephropathy in patients and experimental diabetic animals with in sulin-dependent diabetes mellitus (IDDM). Several mechanisms, such as enhanced activity of angiotensin and vasodilatory prostanoids have been put forward to explain the increased GFR and glomeru lar filtration pressure. Because it is known that PKC activation is involved in enhanced angiotensin action (16) and PGE2 production (13), it is possible that PKC activation can playa role in causing glomerular hyperfiltration in diabetes by enhancing the action of these hormones.
Dysfunctional activity of nitric oxide (NO), an endothelium-derived molecule with profound vasodilatory effects, has been known to be associated with abnormalities of blood flow and contractility in the diabetic state. Excessive NO production, possibly by enhanced inducible NO synthase (iNOS) expression and NO production in mesangial cells, has been postulated to playa role in the increase in blood flow seen in the diabetic kidney (17) . This increased iNOS expression and NO production can be induced by PKC agonists and inhibited by PKC inhibitors (17) , strongly suggesting that PKCinduced iNOS overexpression is associated with increased NO production in dia betic state.
In contrast, it has been reported that NO production and cyclic guanosine monophosphate (cGMP) generation in response to cholinergic stimuli are decreased in glomeruli isolated from diabetic rats and that PKC inhibitors restore the decreased glomeru lar cGMP response (18) .
Although the role of NO in the development and progression of diabetic renal disease still needs to be clarified, it is very possible that PKC can regulate renal hemodynamics by increasing or decreasing NO production depending on the cell type and tissue location. This possibility is being studied.
Hemodynamic abnormalities are also apparent in the early stage of diabetic retinopathy. Kunisaki et al (19) , Bursell et al (20) , and others have reported that retinal blood flow was decreased in diabetic patients and animals with short duration of disease. Many studies have supported PKC activation being involved in decreasing retinal blood flow. Intravitreal injection ofphorbol esters, a PKC agonist, can decrease retinal blood flow (19) . In addition, retinal blood-flow abnormalities found in diabetic rats were normalized by intravitreous introduction ofPKC inhibitors, supporting the observation that PKC activation may play an important role in the genesis of retinal hemodynamic abnormalities.
Although the mechanism explaining how PKC activation can cause retinal vasoconstriction has not been identified yet, one of the possible mechanisms is an increase of endothelin-1 (ET-1) expression in the diabetic retina, ET-1 being the most potent vasoconstrictor. Direct application of ET -1 intravitreously caused sustained retinal vasoconstriction and decreased blood flow in non diabetic rats (19) . We have reported that ET-1 gene expression was increased in diabetic rat retina and that decreased blood flow in diabetic retina can be normalized by endothelin -A (ET A) receptor antagonist BQ123 (21) . Local retinal hypoxia, which is induced by decrease in blood flow to the retina, can induce vascular endothelial growth factor (VEGF) expression, causing increase in perme ability, microaneurysms, and new vessel formation. Hyperglycemia has been reported to enhance the se cretion ofET -1 from cultured bovine aortic endothelial cells (22) ; however, the mechanism by which diabetic state can increase ET-1 expression in the retina is not clarified and is being investigated.
In the large vessels of diabetic patients, delayed or blunted relaxation after acetylcholine stimulation has been observed, and this impaired vascular re laxation can be mimicked by PKC activation using phorbol esters and can be reversed by PKC inhibitors (23) .
Vasodilatory effects ofinsulin are well recognized, and evidence exists that this effect of insulin is partly mediated by nitric oxide. The insulin-induced NO production is known to be mediated by phosphatidylinositol-3-kinase (PI3K) pathway (24) . Interestingly, PKC activation can inhibit insulin's effect on NO pro duction, whereas general PKC and PKC-&#946;-selective inhibitor can enhance endothelial NO synthase (eNOS) expression in endothelial cells (25) . To confirm the involvement ofPKC-&#946;-isoform activation in inhibition of eNOS expression, we studied insulin's effect on NO increase in PKC-&#946;-overexpressed aortic endothelial cells. PKC-&#946;-overexpressed cells were unresponsive to insulin for the induction of eNOS expression, suggesting that PKC, especially &#946;-isoform activation, may be involved in impairment of insulin's vasodilatory effects by increasing eNOS expression in diabetic state or insulin-resistant state.
The results described above strongly suggested that PKC activation plays a general role in causing abnormal microvascular and macrovascular hemodynamics in diabetes.
PERMEABILITY, CELL GROWTH, AND ANGIOGENESIS
PKC activation also can induce increased vascular permeability, cell growth, and neovascularization, which are other hallmarks of diabetic vascular abnormalities. PKC activation can directly increase the vascular permeability of albumin and other macromolecules, probably by phosphorylating cytoskeletal proteins forming the tight junction (26) . PKC activation can also induce increased permeability and angiogenesis via the expression of growth factors, such as the VEGF/vascular permeability factor (VPF) (27) , which we have reported to be implicated in the neovascularization process of proliferative retinopathy. VEGF/VPF is mediating its mitogenic and permeabilityinducing actions by activating PKC &#946;-isoform through tyrosine phosphorylation ofPLC (28) . A PKC B selective inhibitor, LY333531, can decrease VEGF-induced proliferation, angiogenesis, and permeability (29) . These studies have provided further support that PKC activation is partially responsible for these abnormalities in vascular tissues.
EFFECTS OF PKC INHIBITION ON VASCULAR ABNORMALITIES IN DIABETES
The most direct way to prove the in vivo role of PKC activation in the development of diabetic complications is to determine the effect ofPKC normalization on the development and progression of diabetic vascular abnormalities. To achieve this goal, we studied the effects of two different kinds ofPKC inhibitors, Vitamin E (d-&#945;-tocopherol) and a specific inhibitor for PKC &#946;-isoform, LY333531.
Vitamin E: Vitamin E is a well-known antioxidant, but it has been known to have an additional effect of preventing the activation of PKC in cultured vascular cells exposed to elevated glucose levels. We have reported that vitamin E does not inhibit PKC activation directly but indirectly, by decreasing DAG levels (12) . Previously, we reported that direct application of vitamin E to purified PKC &#945; isoform or &#946;-isoform had no inhibitory effect. Recently, we found that vitamin E can attenuate DAG-PKC pathway activation via activation ofDAG kinase (29) , which metabolizes DAG to phosphatidic acid, thus decreasing DAG levels and PKC activity.
Recently, we confirmed the in viva effect of vitamin E in diabetic rats. Intraperitoneal injection of vitamin E can prevent the increase in DAG level and PKC activity in the retina, aorta, heart, and renal glomeruli of streptozotocininduced diabetic rats, and can also improve the functional abnormalities, such as decreased retinal blood flow, glomerular hyperfiltration, and albuminuria (19, 29) . These studies strongly suggested that increased DAG level is a main cause for PKC activation induced by diabetes or hyperglycemia, and that PKC activation is responsible for the various functional abnormalities observed in diabetes.
LY333531, a Selective PKC-&#946; Inhibitor: Because PKC plays many important roles in various cellular functions that are essential for survival, non specific inhibition ofPKC can lead to severe toxicity to cells. Previously known PKC inhibitors, such as staurosporine, H 7, and G F109203X, inhibit not only all kinds ofPKC isoforms, but also affect other kinases; they can therefore be quite toxic, especially when used chronically. Because the PKC &#946;-isoform is predomi nantly increased in diabetic retina, kidney, and cardiovascular tissues, a specific inhibitor for PKC &#946;-isoform should be effective and less toxic than general PKC inhibitors. We synthesized a selective inhibitor ofPKC &#946; -isoform, LY333531, which was 50 to lOO times more potent for PKC &#946;-isoforms than for most other PKC isoforms, and which did not inhibit other kinases.
Recently, we showed that oral treatment using LY333531 for up to 12 weeks in diabetic rats can pre vent or reverse abnormalities of retinal blood flow, glomerular hyperfiltration, and renal albumin excretion in a dose-dependent manner (7) . These results also indicate that the activation of PKC &#946;-isoform is involved in many of the vascular diseases induced by diabetes.
CONCLUSION
Multiple lines ofin vitro and in vivo evidence have clearly established that activation of the DAG-PKC pathway by hyperglycemia is responsible for many of the vascular abnormalities observed in diabetes. The results of studies using PKC-&#946;-selective inhibitor and vitamin E have also confirmed the role ofPKC activation in the pathogenesis of diabetic vascular complications.
However, because most of the studies were performed in animal models, it may be possible that different PKC isoforms are activated in the vasculature of diabetic patients. Thus, human studies are needed to confirm the results found in animal models ofdiabetes. To clarify the pathogenic role of the DAG-PKC pathway in the development ofvascular complications in diabetic patients, investigations including longterm clinical trials are needed to clarify the usefulness ofLY333531 and of vitamin E in preventing and halting the development of diabetic complications.
